A trial to evaluate the early toxicity of radiotherapy (RT), pertuzumab (P) and trastuzumab (T) in patients (pts) treated for HER2 positive metastatic and/or locally recurrent unresectable breast cancer

Trial Profile

A trial to evaluate the early toxicity of radiotherapy (RT), pertuzumab (P) and trastuzumab (T) in patients (pts) treated for HER2 positive metastatic and/or locally recurrent unresectable breast cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top